Market Cap (In KRW)
195.69 Billion
Revenue (In KRW)
4.87 Billion
Net Income (In KRW)
-48.92 Billion
Avg. Volume
119.91 Thousand
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2015.0-4385.0
- PE
- -
- EPS
- -
- Beta Value
- 0.015554
- ISIN
- KR7083790006
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Joong-Myung Cho Ph.D.
- Employee Count
- -
- Website
- https://www.cgxinc.com
- Ipo Date
- 2006-01-06
- Details
- CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
More Stocks
-
6605
-
1423
-
BINANIINDBinani Industries Limited
BINANIIND
-
PBIGF
-
CANDLE-BCandles Scandinavia AB (publ)
CANDLE-B
-
ZAPZaptec AS
ZAP
-
ENDYEndymed Ltd
ENDY
-
KZG